These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 25823821)
1. Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development. Deng R; Zhao X; Qu Y; Chen C; Zhu C; Zhang H; Yuan H; Jin H; Liu X; Wang Y; Chen Q; Huang J; Yu J Oncotarget; 2015 Apr; 6(11):9355-69. PubMed ID: 25823821 [TBL] [Abstract][Full Text] [Related]
2. SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development. Kang HJ; Chung DH; Sung CO; Yoo SH; Yu E; Kim N; Lee SH; Song JY; Kim CJ; Choi J Oncotarget; 2017 Apr; 8(16):27263-27276. PubMed ID: 28460481 [TBL] [Abstract][Full Text] [Related]
3. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase. Miura K; Wakayama Y; Tanino M; Orba Y; Sawa H; Hatakeyama M; Tanaka S; Sabe H; Mochizuki N Oncogene; 2013 Nov; 32(45):5292-301. PubMed ID: 23318428 [TBL] [Abstract][Full Text] [Related]
4. Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk. Zhang J; Lan SJ; Liu QR; Liu JM; Chen XQ Mol Pharmacol; 2013 May; 83(5):1109-19. PubMed ID: 23478801 [TBL] [Abstract][Full Text] [Related]
5. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor. Meng S; Chen Z; Munoz-Antonia T; Wu J Biochem J; 2005 Oct; 391(Pt 1):143-51. PubMed ID: 15952937 [TBL] [Abstract][Full Text] [Related]
6. Oncogenic Shp2 disturbs microtubule regulation to cause HDAC6-dependent ERK hyperactivation. Tien SC; Chang ZF Oncogene; 2014 May; 33(22):2938-46. PubMed ID: 23770849 [TBL] [Abstract][Full Text] [Related]
7. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma. Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822 [TBL] [Abstract][Full Text] [Related]
8. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells. McPherson VA; Sharma N; Everingham S; Smith J; Zhu HH; Feng GS; Craig AW J Immunol; 2009 Oct; 183(8):4940-7. PubMed ID: 19786542 [TBL] [Abstract][Full Text] [Related]
9. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment. Chen WS; Liang Y; Zong M; Liu JJ; Kaneko K; Hanley KL; Zhang K; Feng GS Cell Rep; 2021 Nov; 37(6):109974. PubMed ID: 34758313 [TBL] [Abstract][Full Text] [Related]
10. Excitatory neuron-specific SHP2-ERK signaling network regulates synaptic plasticity and memory. Ryu HH; Kim T; Kim JW; Kang M; Park P; Kim YG; Kim H; Ha J; Choi JE; Lee J; Lim CS; Kim CH; Kim SJ; Silva AJ; Kaang BK; Lee YS Sci Signal; 2019 Mar; 12(571):. PubMed ID: 30837304 [TBL] [Abstract][Full Text] [Related]
11. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227 [TBL] [Abstract][Full Text] [Related]
12. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration. Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220 [TBL] [Abstract][Full Text] [Related]
13. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. Han T; Xiang DM; Sun W; Liu N; Sun HL; Wen W; Shen WF; Wang RY; Chen C; Wang X; Cheng Z; Li HY; Wu MC; Cong WM; Feng GS; Ding J; Wang HY J Hepatol; 2015 Sep; 63(3):651-60. PubMed ID: 25865556 [TBL] [Abstract][Full Text] [Related]
14. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. Sun CK; Man K; Ng KT; Ho JW; Lim ZX; Cheng Q; Lo CM; Poon RT; Fan ST Carcinogenesis; 2008 Nov; 29(11):2096-105. PubMed ID: 18765415 [TBL] [Abstract][Full Text] [Related]
15. Mechanism study of tyrosine phosphatase shp-1 in inhibiting hepatocellular carcinoma progression by regulating the SHP2/GM-CSF pathway in TAMs. Wei Q; Luo S; He G Sci Rep; 2024 Apr; 14(1):9128. PubMed ID: 38644382 [TBL] [Abstract][Full Text] [Related]
16. Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2. Chen C; Cao M; Zhu S; Wang C; Liang F; Yan L; Luo D Sci Rep; 2015 Dec; 5():17626. PubMed ID: 26626996 [TBL] [Abstract][Full Text] [Related]
18. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412 [TBL] [Abstract][Full Text] [Related]
19. Sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein (SPRED1), a tyrosine-protein phosphatase non-receptor type 11 (SHP2) substrate in the Ras/extracellular signal-regulated kinase (ERK) pathway. Quintanar-Audelo M; Yusoff P; Sinniah S; Chandramouli S; Guy GR J Biol Chem; 2011 Jul; 286(26):23102-12. PubMed ID: 21531714 [TBL] [Abstract][Full Text] [Related]